{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:46:08Z","timestamp":1784630768382,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T00:00:00Z","timestamp":1592006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T00:00:00Z","timestamp":1592006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The accumulation of misfolded tau is a common feature of several neurodegenerative disorders, with Alzheimer\u2019s disease (AD) being the most common. Earlier we identified JNJ-64326067, a novel isoquinoline derivative with high affinity and selectivity for tau aggregates from human AD brain. We report the dosimetry of [<jats:sup>18<\/jats:sup>F] JNJ-64326067 and results of a proof-of-concept study comparing subjects with probable Alzheimer\u2019s disease to age-matched healthy controls.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>[<jats:sup>18<\/jats:sup>F] JNJ-64326067 PET scans were acquired for 90\u00a0min and then from 120 to 180\u00a0min in 5 participants with [<jats:sup>18<\/jats:sup>F]-florbetapir PET amyloid positive probable AD (73\u2009\u00b1\u20099\u00a0years) and 5 [<jats:sup>18<\/jats:sup>F]-florbetapir PET amyloid negative healthy controls (71\u2009\u00b1\u20097\u00a0years). Whole-body [<jats:sup>18<\/jats:sup>F] JNJ-64326067 PET CT scans were acquired in six healthy subjects for 5.5\u00a0h in 3 scanning sessions. Brain PET scans were visually reviewed. Regional quantification included kinetic analysis of distribution volume ration (DVR) estimated by Logan graphical analysis over the entire scan and static analysis of SUVr in late frames. Both methods used ventral cerebellar cortex as a reference region.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One of the healthy controls had focal areas of PET signal in occipital and parietal cortex underlying the site of a gunshot injury as an adolescent; the other four healthy subjects had no tau brain signal. Four of the 5 AD participants had visually apparent retention of [<jats:sup>18<\/jats:sup>F] JNJ-64326067 in relevant cortical regions. One of the AD subjects was visually negative. Cortical signal in visually positive subjects approached steady state by 120\u00a0min. Temporal and frontal cortical SUVr\/DVR values in visually positive AD subjects ranged from 1.21 to 3.09\/1.2 to 2.18 and from 0.92 to 1.28\/0.91 to 1.16 in healthy controls. Whole-body effective dose was estimated to be 0.0257\u00a0mSv\/MBq for females and 0.0254\u00a0mSv\/MBq for males.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>[<jats:sup>18<\/jats:sup>F] JNJ-64326067 could be useful for detection and quantitation of tau aggregates.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-020-04880-1","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T04:02:33Z","timestamp":1592020953000},"page":"3176-3185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"47","author":[{"given":"Mark E.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik","family":"Moechars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik J. R.","family":"Rombouts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian C.","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Madonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Sandiego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmuth","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,13]]},"reference":[{"issue":"8","key":"4880_CR1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jalz.2018.03.005","volume":"14","author":"R Brookmeyer","year":"2018","unstructured":"Brookmeyer R, Abdalla N. Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 2018;14(8):981\u20138.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"4880_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539\u201347.","journal-title":"Neurology."},{"issue":"2","key":"4880_CR3","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3233\/JAD-122059","volume":"34","author":"DT Chien","year":"2013","unstructured":"Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457\u201368.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"4880_CR4","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1021\/jm5017544","volume":"58","author":"M Ariza","year":"2015","unstructured":"Ariza M, Kolb HC, Moechars D, Rombouts F, Andres JI. Tau positron emission tomography (PET) imaging: past, present, and future. J Med Chem. 2015;58(11):4365\u201382.","journal-title":"J Med Chem"},{"key":"4880_CR5","doi-asserted-by":"publisher","unstructured":"Baker SL, Harrison TM, Maass A, La Joie R, Jagust W. Effect of off-target binding on (18)F-Flortaucipir variability in healthy controls across the lifespan. J Nucl Med. 2019;60:1444\u20131451. https:\/\/doi.org\/10.2967\/jnumed.118.224113.","DOI":"10.2967\/jnumed.118.224113"},{"issue":"10","key":"4880_CR6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2967\/jnumed.115.170027","volume":"57","author":"S Shcherbinin","year":"2016","unstructured":"Shcherbinin S, Schwarz AJ, Joshi A, Navitsky M, Flitter M, Shankle WR, et al. Kinetics of the tau PET tracer 18F-AV-1451 (T807) in subjects with Normal cognitive function, mild cognitive impairment, and Alzheimer disease. J Nucl Med. 2016;57(10):1535\u201342.","journal-title":"J Nucl Med"},{"issue":"4","key":"4880_CR7","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1021\/acs.jmedchem.6b01173","volume":"60","author":"FJR Rombouts","year":"2017","unstructured":"Rombouts FJR, Andr\u00e9s J-I, Ariza M, Alonso JM, Austin N, Bottelbergs A, et al. Discovery of N-(Pyridin-4-yl)-1,5-naphthyridin-2-amines as potential tau pathology PET tracers for Alzheimer\u2019s disease. J Med Chem. 2017;60(4):1272\u201391.","journal-title":"J Med Chem"},{"issue":"6","key":"4880_CR8","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1021\/acs.jmedchem.8b01759","volume":"62","author":"FJR Rombouts","year":"2019","unstructured":"Rombouts FJR, Declercq L, Andres JI, Bottelbergs A, Chen L, Iturrino L, et al. Discovery of N-(4-[(18)F]Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a new promising tau positron emission tomography imaging tracer. J Med Chem. 2019;62(6):2974\u201387.","journal-title":"J Med Chem"},{"issue":"1","key":"4880_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-017-0253-y","volume":"9","author":"KP Ng","year":"2017","unstructured":"Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, et al. Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9(1):25.","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"4880_CR10","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","volume":"57","author":"ED Hostetler","year":"2016","unstructured":"Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57(10):1599\u2013606.","journal-title":"J Nucl Med"},{"issue":"2","key":"4880_CR11","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.neuroimage.2007.11.034","volume":"40","author":"IS Gousias","year":"2008","unstructured":"Gousias IS, Rueckert D, Heckemann RA, Dyet LE, Boardman JP, Edwards AD, et al. Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest. Neuroimage. 2008;40(2):672\u201384.","journal-title":"Neuroimage."},{"issue":"4","key":"4880_CR12","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hbm.10123","volume":"19","author":"A Hammers","year":"2003","unstructured":"Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19(4):224\u201347.","journal-title":"Hum Brain Mapp"},{"issue":"5","key":"4880_CR13","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","volume":"16","author":"J Logan","year":"1996","unstructured":"Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834\u201340.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3 Pt 1","key":"4880_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1006\/nimg.1996.0066","volume":"4","author":"AA Lammertsma","year":"1996","unstructured":"Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4(3 Pt 1):153\u20138.","journal-title":"Neuroimage."},{"issue":"1","key":"4880_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2967\/jnumed.118.209650","volume":"60","author":"TJ Betthauser","year":"2019","unstructured":"Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand (18)F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60(1):93\u20139.","journal-title":"J Nucl Med"},{"issue":"4","key":"4880_CR16","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/brain\/awy049","volume":"141","author":"H Botha","year":"2018","unstructured":"Botha H, Mantyh WG, Murray ME, Knopman DS, Przybelski SA, Wiste HJ, et al. FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain. 2018;141(4):1201\u201317.","journal-title":"Brain"},{"issue":"2","key":"4880_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0006-8993(94)91136-3","volume":"648","author":"N Selden","year":"1994","unstructured":"Selden N, Mesulam MM, Geula C. Human striatum: the distribution of neurofibrillary tangles in Alzheimer's disease. Brain Res. 1994;648(2):327\u201331.","journal-title":"Brain Res"},{"issue":"2","key":"4880_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1148\/radiol.10100495","volume":"257","author":"C Langkammer","year":"2010","unstructured":"Langkammer C, Krebs N, Goessler W, Scheurer E, Ebner F, Yen K, et al. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology. 2010;257(2):455\u201362.","journal-title":"Radiology."},{"issue":"18","key":"4880_CR19","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1056\/NEJMoa1900757","volume":"380","author":"RA Stern","year":"2019","unstructured":"Stern RA, Adler CH, Chen K, Navitsky M, Luo J, Dodick DW, et al. Tau positron-emission tomography in former National Football League players. N Engl J Med. 2019;380(18):1716\u201325.","journal-title":"N Engl J Med"},{"issue":"7752","key":"4880_CR20","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41586-019-1026-5","volume":"568","author":"B Falcon","year":"2019","unstructured":"Falcon B, Zivanov J, Zhang W, Murzin AG, Garringer HJ, Vidal R, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019;568(7752):420\u20133.","journal-title":"Nature."},{"issue":"2","key":"4880_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7(2):129\u201335.","journal-title":"Lancet Neurol"},{"issue":"6","key":"4880_CR22","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2967\/jnumed.109.069088","volume":"51","author":"DF Wong","year":"2010","unstructured":"Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51(6):913\u201320.","journal-title":"J Nucl Med"},{"issue":"1","key":"4880_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0006-8993(84)91113-2","volume":"305","author":"JJ Frost","year":"1984","unstructured":"Frost JJ, Wagner HN Jr. Kinetics of binding to opiate receptors in vivo predicted from in vitro parameters. Brain Res. 1984;305(1):1\u201311.","journal-title":"Brain Res"},{"issue":"11","key":"4880_CR24","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00259-013-2512-x","volume":"40","author":"P Zanotti-Fregonara","year":"2013","unstructured":"Zanotti-Fregonara P, Lammertsma AA, Innis RB. Suggested pathway to assess radiation safety of (1)(8)F-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2013;40(11):1781\u20133.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4880_CR25","unstructured":"Food and Drug Administration. Title 21 CFR 361.1. Radioactive drugs for certain research uses. Washington DC: National Archives and Records Administration. Office of the Federal Register; 2011. p. 325\u201330."},{"key":"4880_CR26","unstructured":"International Commission on Radiological Protection (ICRP) ICRP Publication 62: radiological protection in biomedical research. 1992."},{"issue":"12","key":"4880_CR27","first-page":"1959","volume":"46","author":"BJ Lopresti","year":"2005","unstructured":"Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46(12):1959\u201372.","journal-title":"J Nucl Med"},{"issue":"12","key":"4880_CR28","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.2967\/jnumed.118.214437","volume":"59","author":"H Kuwabara","year":"2018","unstructured":"Kuwabara H, Comley RA, Borroni E, Honer M, Kitmiller K, Roberts J, et al. Evaluation of (18)F-RO-948 PET for quantitative assessment of tau accumulation in the human brain. J Nucl Med. 2018;59(12):1877\u201384.","journal-title":"J Nucl Med"},{"issue":"1","key":"4880_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110\u20139.","journal-title":"Ann Neurol"},{"issue":"1","key":"4880_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2967\/jnumed.116.176628","volume":"58","author":"G Leurquin-Sterk","year":"2017","unstructured":"Leurquin-Sterk G, Celen S, Van Laere K, Koole M, Bormans G, Langlois X, et al. What we observe in vivo is not always what we see in vitro: development and validation of 11C-JNJ-42491293, a novel radioligand for mGluR2. J Nucl Med. 2017;58(1):110\u20136.","journal-title":"J Nucl Med"},{"issue":"1","key":"4880_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13550-017-0314-z","volume":"7","author":"M Schain","year":"2017","unstructured":"Schain M, Fazio P, Mrzljak L, Amini N, Al-Tawil N, Fitzer-Attas C, et al. Revisiting the Logan plot to account for non-negligible blood volume in brain tissue. EJNMMI Res. 2017;7(1):66.","journal-title":"EJNMMI Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04880-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-020-04880-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04880-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T23:14:29Z","timestamp":1623539669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-020-04880-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,13]]},"references-count":31,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4880"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-04880-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,13]]},"assertion":[{"value":"10 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. Study protocols and informed consents were reviewed and approved by New England IRB; 197 First Avenue; Suite 250; Needham MA 02494; , and by the FDA prior to study execution.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Mark E. Schmidt, Luc Janssens, Diederik Moechars, Frederik J.R. Rombouts, Maarten Timmers, and Hartmuth Kolb are all full time employees of Janssen Research & Development, which provided funding and oversight of these studies and supported the discovery and preclinical characterization of JNJ-6436067. Olivier Barret, Cristian C. Constantinescu, Jennifer Madonia, David S. Russell, and Christine M. Sandiego are or were (OB, JM) full time employees of Invicro, a Konica Minolta company, New Haven, CT, USA, at the time of these studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}